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Introduction: The Spanish COPD guideline (GesEPOC) classifies COPD into four clinical 
phenotypes based on the exacerbation frequency and dominant clinical manifestations. In this 
study, we compared the disease-specific health-related quality of life (HRQoL) of patients with 
different clinical phenotypes.
Methods: This was a cross-sectional study of patients with COPD attending the respiratory 
medicine clinic of University of Malaya Medical Centre from 1 June 2017 to 31 May 2018. 
Disease-specific HRQoL was assessed by using the COPD Assessment Test (CAT) and 
St George’s Respiratory Questionnaire for COPD (SGRQ-c).
Results: Of 189 patients, 28.6% were of non-exacerbator phenotype (NON-AE), 18.5% were 
of exacerbator with emphysema phenotype (AE NON-CB), 39.7% were of exacerbator with 
chronic bronchitis phenotype (AE CB), and 13.2% had asthma-COPD overlap syndrome phe-
notype (ACOS). The total CAT and SGRQ-c scores were significantly different between the 
clinical phenotypes (P,0.001). Patients who were AE CB had significantly higher total CAT 
score than those with ACOS (P=0.033), AE NON-CB (P=0.001), and NON-AE (P,0.001). 
Concerning SGRQ-c, patients who were AE CB also had a significantly higher total score than 
those with AE NON-CB (P=0.001) and NON-AE (P,0.001). However, the total SGRQ-c score 
of AE CB patients was only marginally higher than those who had ACOS (P=0.187). There was 
a significant difference in the score of each CAT item (except CAT 7) and SGRQ-c components 
between clinical phenotypes, with AE CB patients recording the highest score in each of them.
Conclusion: Patients who were AE CB had significantly poorer HRQoL than other clinical 
phenotypes and recorded the worst score in each of the CAT items and SGRQ-c components. 
Therefore, AE CB patients may warrant a different treatment approach that focuses on the 
exacerbation and chronic bronchitis components.
Keywords: chronic obstructive pulmonary disease, chronic bronchitis, asthma, clinical phe-
notypes, health-related quality of life, emphysema, exacerbation
Introduction
COPD is a common, preventable, and treatable airway disease characterized by 
persistent respiratory symptoms and airflow limitation, due to abnormal inflammatory 
response of the airways to noxious particles or gases.1 It is currently the fourth leading 
cause of death in the world. It is also expected to become the third leading cause of 
death, and fifth leading cause of disease burden by 2020.2,3 The overall prevalence of 
COPD in the Asia-Pacific region is 6.2%.4 COPD population represents a substantial 
socioeconomic burden in these countries as two-fifth of them have work restriction, 
one-fifth has severe respiratory symptoms, and one-fifth had required hospital admis-
sion in the past 12-months because of exacerbation.4
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COPD phenotype refers to a single or combination of 
disease attributes that describe differences between COPD 
patients based on clinically significant parameters, such as 
exacerbation, symptoms, response to treatment, rate of dis-
ease progression, and mortality.5 In 2012, the Spanish Society 
of Pulmonology and Thoracic Surgery published the Spanish 
COPD guideline (GesEPOC), which was the first clinical 
guideline that phenotypes COPD patients based on their 
exacerbation frequency and dominant clinical manifestations, 
such as bronchitis, emphysema, and bronchial asthma (BA).6 
Even though many existing data report on the health-related 
quality of life (HRQoL) of COPD patients, studies that com-
pare HRQoL among different clinical phenotypes simultane-
ously are lacking.
HRQoL is defined as individual satisfaction or happiness 
with an aspect of their life that is affected by their health 
either in physical, mental, emotional, or social functioning.7 
Poor HRQoL is associated with increased level of dyspnea, 
physical impairment, mental health problem, hospital 
admission, and mortality.8–10 HRQoL of COPD patients 
can be measured by using generic questionnaires, such as 
Short Form Survey-36 and Euro-Qol-5D; or disease-spe-
cific questionnaires, such as COPD Assessment Test (CAT), 
St Georges Respiratory Questionnaire for COPD (SGRQ-c), 
and Clinical COPD Questionnaire (CCQ).11,12
In this study, we aimed to compare the disease-specific 
HRQoL of patients with COPD attending the University of 
Malaya Medical Centre (UMMC) based on their clinical 
phenotype as defined by the GesPOC guideline. UMMC is 
a tertiary teaching hospital, located in Kuala Lumpur, the 
capital of Malaysia.
Methods
study design and patients
This is a cross-sectional study of patients with COPD attending 
the respiratory medicine clinic of UMMC from 1 June 2017 
to 31 May 2018. All patients studied were aged $40 years, 





post-bronchodilator FVC of ,0.7. Patients with concomitant 
BA were included, but patients with other chronic lung dis-
eases, such as bronchiectasis or interstitial lung disease were 
excluded. The estimated sample size (n) was 155 patients, 
calculated based on the reported COPD prevalence of 11.4%, 
Zα of 1.96, and precision of 0.05.
13 This study aimed to deter-
mine the impact of different COPD clinical phenotypes on 
patients’ disease-specific HRQoL assessed by using CAT 
and SGRQ-c. The primary objective was to compare the total 
CAT and SGRQ-c score of different clinical phenotypes; 
while the secondary objective was to compare the score of 
individual items of CAT and each component of SGRQ-c of 
different clinical phenotypes. The hospital’s ethics committee 
approved this study. Written informed consent was obtained 
from all the study patients. This study was conducted in 
accordance with the Declaration of Helsinki.
Procedure
Eligible patients were consecutively identified from those 
attending the respiratory medicine clinic. Demographic and 
clinical data of these patients were obtained from face-to-face 
interview and case records.
Patients were categorized as never-smokers if they had 
smoked ,100 cigarettes in their lifetime; previous smokers 
if they had smoked .100 cigarettes in their lifetime and no 
more smoking; and current smokers if they had smoked .100 
cigarettes in their lifetime and still smoking every day or 
some of the days.14 The patients’ dyspnea was graded accord-
ing to the modified Medical Research Council scale that 
consists of five grades: 0 – no dyspnea except on strenuous 
activity; 1) dyspnea when walking uphill; 2) walk slower than 
people with same age due to dyspnea; 3) stops for breath due 
to dyspnea after walking 100 m at level; and 4) too dyspnoeic 
to leave home or dyspnea when dressing.15
PB-FEV
1
 was expressed in % of predicted (PB-FEV
1
 %). 
Total exacerbation only considered the number of moderate 
and severe exacerbations. A moderate exacerbation was 
defined as an exacerbation that required outpatient treatment 
with corticosteroid and/or antibiotic; while severe exacerba-
tion was defined as an exacerbation that needed hospital 
admission.16 For patients on COPD treatment, a new episode 
of exacerbation required at least 4 weeks from the resolution 
of a previous exacerbation; while for patients not on COPD 
treatment, a new episode of exacerbation required at least 
6 weeks from the last exacerbation.17 Chronic bronchitis (CB) 
was defined as a cough with sputum for at least 3 months in 
a year for 2 consecutive years.18 In the presence of COPD, 
BA was defined as those already currently diagnosed with 
BA or had very definite PB-FEV
1
 improvement of .400 mL 
and 15%, or blood eosinophil of .300 cells/mm.3,19
The COPD clinical phenotypes were defined according 
to the GesEPOC guideline.20 Non-exacerbator phenotype 
(NON-AE) was defined by the presence of ,2 episodes of 
moderate exacerbation and without severe exacerbation in the 
past 1 year. Exacerbator phenotype (AE) was defined by the 
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an episode of severe exacerbation in the past 1 year. This phe-
notype was further divided into AE with CB phenotype (AE 
CB) and AE with emphysema phenotype (AE NON-CB). 
The former phenotype was defined by the presence of CB; 
while the latter phenotype was defined by the presence of 
air-trapping on examination or investigations. Asthma-COPD 
overlap syndrome phenotype (ACOS) was defined by the 
presence of BA criteria as mentioned previously without the 
consideration of the number of exacerbation.
In assessing HRQoL, the patients were instructed to answer 
the CAT and SGRQ-c questionnaires independently with 
minimal assistance from the investigators. The patients could 
choose to answer the original English version, or validated 
Malay or Chinese version. The CAT questionnaire consists of 
eight items, namely, cough (CAT 1), phlegm (CAT 2), chest 
tightness (CAT 3), breathlessness (CAT 4), activity limita-
tion (CAT 5), confidence in leaving home (CAT 6), sleep 
(CAT 7), and energy (CAT 8).21 The score for each of these 
items ranges from 0 to 5 with the total score ranging from 0 
to 40. The total CAT score in a healthy subject is #6, with a 
higher score reflecting a greater or worse impact of COPD on 
HRQoL.22 The SGRQ-c questionnaire consists of 14 questions, 
with questions 1–7 interrogating the symptom component, 
questions 9 and 12 concerning activity component, and ques-
tions 8, 10, 11, 13, and 14 relating to impact component.23 The 
score of each component and the total score range from 0% to 
100%, with a higher score reflecting worse HRQoL. In healthy 
subjects, the score of the total is #6%, symptom component 
is #12%, activity component is #9%, and impact component 
is not .2%.24 CAT is a quick assessment tool, while SGRQ-c 
is more comprehensive but time-consuming.
statistical analyses
In this study, categorical variables were expressed as per-
centages; while continuous variables were expressed as the 
mean ± SD, median or range depending on the normality of 
the distribution of the variable. For categorical variables, the 
difference between clinical phenotypes was compared by 
using the chi-squared test. An adjusted standardized residual 
of .2 was considered as significant in the post hoc analysis. 
For continuous variables, the difference between clinical 
phenotypes was compared by using one-way ANOVA 
test or Kruskal–Wallis H test, as applicable. The post hoc 
analysis for the former was the Tukey’s test, while for the 
latter, was the Dunn’s procedure with a Bonferroni adjust-
ment. A P-value of ,0.05 was considered statistically 
significant. Statistical analyses were performed using the 
software package, SPSS for Windows version 23.0 (SPSS 
Inc., Chicago, IL, USA).
Results
Demographic and clinical characteristics
A total of 189 patients who met the study criteria were 
included in the study (Figure 1). Patients’ demographic and 
clinical characteristics are shown in Table 1. A total of 28.6% 
of patients were of NON-AE, 18.5% were of AE NON-CB, 
39.7% were of AE CB, and 13.2% had ACOS. Among 
patients of NON-AE, 46.3% were of CB and 53.7% were of 
NON-CB. Regardless of the phenotypes, male patients were 
predominant and the majority of the patients were ex-smokers. 
The age, gender proportion, ethnicity distribution, smoking 
status, and smoking quantity difference among the patients 
with the different clinical phenotypes were not significant.
The dyspnea symptom (P=0.002), PB-FEV
1
 % (P=0.025), 
and total exacerbation (P,0.001) were significantly different 
between clinical phenotypes. Patients who were of AE CB 
had significantly worse dyspnea symptom (P=0.002), lower 
PB-FEV
1
 % (P=0.018), and higher total number of exacerba-
tions (P,0.01) than patients of NON-AE. The total number 
of exacerbations was also significantly higher in patients who 
had ACOS (P,0.001) and AE NON-CB (P,0.001) com-
pared with patients of NON-AE. Despite the total number of 
exacerbations for patients with ACOS was also higher than 
that of AE NON-CB (3.4±5.2 vs 1.9±1.9), this difference 
was not statistically significant (P=0.999).
hrQol according to clinical phenotypes
The total CAT and SGRQ-c scores were significantly dif-
ferent between clinical phenotypes (all P-values ,0.001) 
(Table 2). Patients who were of AE CB had significantly 
higher total CAT score than those with ACOS (23.6±8.0 vs 
18.3±10.1, P=0.033), AE NON-CB (23.6±8.0 vs 15.8±8.0, 
P=0.001), and NON-AE (23.6±8.0 vs 18.0±8.0, P,0.001). 
In terms of SGRQ-c, patients who were of AE CB also had 
significant higher total score than those with AE NON-CB 
(61.5±20.9 vs 44.0±21.4, P=0.001) and NON-AE (61.5±20.9 
vs 42.6±20.1, P,0.001). However, the total SGRQ-c score of 
patients with AE CB was only marginally higher than those 
who had ACOS (61.5±20.9 vs 51.5±25.9, P=0.187). Although 
the total CAT score increased from patients who were of AE 
NON-CB, to NON-AE, and ACOS; while the total SGRQ-c 
score increased from patients who were of NON-AE, to AE 
NON-CB, and ACOS, the differences between these clinical 
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There was a significant difference in the score of each 
CAT items (except CAT 7) and SGRQ-c components 
between clinical phenotypes (Table 2). Patients with AE CB 
had the highest score in each of the CAT items and SGRQ-c 
components (Figures 2 and 3). Patients who had ACOS had 
the second highest score in each of the SGRQ-c components 
and CAT 1, CAT 3, CAT 6, and CAT 7. CAT 4 had the 
highest score regardless of the patients’ clinical phenotype.
Discussion
Regardless of the clinical phenotypes, the HRQoL of our 
patients was markedly impaired compared with healthy indi-
viduals. AE CB was the only clinical phenotype associated 
with significantly poorer HRQoL. The poor HRQoL was not 
solely attributable to cough and phlegm symptoms (CAT 1 
and 2), which could be confounded by the definition of CB. 
The sub-analysis of CAT items demonstrated that AE CB was 
associated with more chest tightness, breathlessness, activity 
limitation, fear of leaving home, sleep disturbance, and lack 
of energy (CAT 3–8). Moreover, sub-analysis of SGRQ-c 
components also demonstrated that AE CB was associated 
with more respiratory symptoms and disturbance to daily 
physical activities as well as psychosocial function. Patients 
with ACOS appeared to have poorer HRQoL than those with 
AE NON-CB or NON-AE although the difference was not 
statistically significant, which could be due to the smaller 
number of subjects with ACOS. ACOS was associated with 
more core symptoms of BA, such as a cough, chest tightness, 
and sleep disturbance, while daily activities and energy were 
less affected. Surprisingly, the HRQoL of patients with AE 
NON-CB was not markedly worse than those with NON-AE. 
Such a finding suggests that higher exacerbation frequency 
alone without an unfavorable clinical manifestations might 
not be sufficient to have a detrimental effect on patients’ 
HRQoL. The clinical manifestation that was associated with 
the poorest HRQoL was CB, followed by BA and NON-CB.
From this study, we can conclude that HRQoL is sig-
nificantly worse in patients with AE CB and numerically 
Figure 1 algorithm of patients’ recruitment into the study.
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Table 1 Demographic and clinical characteristics of COPD patients according to their clinical phenotypes































































Dyspnea (mean ± sD; 95% CI) 1.8±1.3; 1.5–2.2 2.0±1.2; 1.6–2.4 2.7±1.1; 2.4–2.9 2.2±1.4; 1.6–2.8 0.002




























Abbreviations: aCOs, asthma-COPD overlap syndrome phenotype; ae CB, exacerbator with chronic bronchitis phenotype; ae nOn-CB, exacerbator with emphysema 
phenotype; nOn-ae, non-exacerbator phenotype; PB-FeV1, post-bronchodilator forced expiratory volume in 1 second.
Table 2 CaT and sgrQ-c scores of COPD patients according to their clinical phenotypes
Parameters COPD phenotype P-value
NON-AE AE NON-CB AE CB ACOS




Chest tightness (CaT 3)
Breathlessness (CaT 4)
activity limitation (CaT 5)




18.0 ± 8.0; 15.8–20.2
2.5 ± 1.2; 2.1–2.8
2.6 ± 1.8; 2.1–3.0
1.4 ± 1.7; 0.9–1.8
3.4 ± 1.7; 3.0–3.9
2.5 ± 1.8; 2.0–3.0
1.7 ± 1.9; 1.2–2.2
1.6 ± 1.6; 1.2–2.1
2.4 ± 1.1; 2.1–2.7
15.8 ± 8.0; 13.1–18.6
2.1 ± 1.3; 1.6–2.5
1.6 ± 1.6; 1.0–2.1
1.7 ± 1.5; 1.2–2.2
3.2 ± 1.5; 2.7–3.7
2.0 ± 1.7; 1.4–2.6
1.6 ± 1.8; 1.0–2.2
1.6 ± 1.6; 1.0–2.1
2.2 ± 1.5; 1.7–2.7
23.6 ± 8.0; 21.8–25.4
3.2 ± 1.2; 2.9–3.5
3.3 ± 1.7; 2.9–3.7
2.6 ± 1.6; 2.2–2.9
4.0 ± 1.3; 3.7–4.2
3.0 ± 1.6; 2.6–3.4
2.4 ± 1.6; 2.1–2.8
2.2 ± 1.6; 1.8–2.5
3.0 ± 1.4; 2.7–3.4
18.3 ± 10.1; 14.0–22.7
2.6 ± 1.6; 2.0–3.3
2.4 ± 1.9; 1.6–3.2
2.2 ± 1.7; 1.5–2.9
3.0 ± 1.7; 2.3–3.7
2.3 ± 1.9; 1.5–3.1
1.9 ± 1.9; 1.1–2.7
1.8 ± 1.8; 1.1–2.5










sgrQ-c score, %  





42.6 ± 20.1; 37.1–48.1
36.8 ± 19.9; 31.4–42.3
48.9 ± 32.5; 40.1–57.8
40.9 ± 20.1; 35.4–46.3
44.0 ± 21.4; 36.6–51.4
43.3 ± 23.6; 35.3–51.5
56.8 ± 27.8; 47.3–66.4
36.9 ± 24.8; 28.4–45.5
61.5 ± 20.9; 56.7–66.3
61.7 ± 20.4; 57.0–66.4
70.5 ± 25.1; 64.7–76.2
56.0 ± 27.2; 49.8–62.3
51.5 ± 25.9; 40.8–62.2
59.2 ± 25.1; 48.9–69.6
58.0 ± 34.6; 43.8–72.3





Abbreviations: aCOs, asthma-COPD overlap syndrome phenotype; ae CB, exacerbator with chronic bronchitis phenotype; ae nOn-CB, exacerbator with emphysema 
phenotype; CaT, COPD assessment Test; nOn-ae, non-exacerbator phenotype; sgrQ-c, st georges respiratory Questionnaire for COPD.
worse in patients with ACOS compared with patients with 
AE NON-CB, and least affected in patients with NON-AE. 
These findings agree with the result of earlier studies. In 
the COPD History Assessment in Spain study, Cosio et al 
reported a significant higher CAT score in patients with AE 
CB (P,0.001), and the CAT score was numerically higher 
in those with ACOS followed by those with AE NON-CB 
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Spain, Miravitlles et al also reported a significant higher CAT 
score in patients with AE CB (P,0.001).26 Those with ACOS 
and AE NON-CB had an intermediate score, while patients 
of NON-AE had the lowest score. A study by Corlateanu et 
al, however, reported that the CAT, SRGQ, and CCQ scores 
were significantly higher in frequent exacerbators; and those 
with AE NON-CB recording the highest values in each of the 
parameters.27 In short, the present study and available data 
consistently highlight that patients with NON-AE had the best 
HRQoL, while patients with frequent exacerbations, particu-
larly of the AE CB phenotype had the worst HRQoL. Our study 
further complements these existing works by demonstrating 
that AE CB phenotype is indeed associated with the worst 
score in each of the CAT items and SGRQ-c components.
In this study, the higher exacerbation frequency and 
active inflammation of CB led to poorer HRQoL in patients 
with the AE CB phenotype. Frequent exacerbation has been 
known to have a profound impact on HRQoL. Seemungal 
et al reported that patients with three or more exacerbations 
per year had significant worse SGRQ score (P,0.001), 
while Mackay et al reported that patients with two or more 
exacerbations per year had significantly worse CAT score 
(P=0.025).28,29 Similarly, CB was reported to be indepen-
dently associated with poorer HRQoL compared with 
Figure 2 score of CaT items according to COPD clinical phenotypes.
Abbreviations: aCOs, asthma-COPD overlap syndrome phenotype; ae CB, exacerbator with chronic bronchitis phenotype; ae nOn-CB, exacerbator with emphysema 
phenotype; CaT, COPD assessment Test; nOn-ae, non-exacerbator phenotype.
Figure 3 Total and component scores of sgrQ-c according to COPD clinical phenotypes.
Abbreviations: aCOs, asthma-COPD overlap syndrome phenotype; ae CB, exacerbator with chronic bronchitis phenotype; ae nOn-CB, exacerbator with emphysema 
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disease-specific HRQoL assessment tools were utilized to 
obtain more representative results. The impact of COPD 
clinical phenotypes on each of the individual CAT items and 
SGRQ-c components was also analyzed.
This study has several limitations. First, it was performed 
in a single center, thus limiting the generalizability of the 
results. Second, there is the possibility of misclassification of 
the clinical phenotypes because the exacerbation frequency 
was subjected to the recall error of the patients. We tried to 
minimize this error by double checking the exacerbation 
history from patients’ available medical records. Finally, 
the number of ACOS patients was disproportionately small 
for statistically significant differences to be achieved when 
comparison of HRQoL was made with the other phenotypes.
Conclusion
This study concluded that patients who were AE CB had 
significant poorer HRQoL than other clinical phenotypes. 
It further complements existing studies by demonstrating 
that patients of AE CB also had the worst score in each of 
the CAT items and SGRQ-c components. Therefore, patients 
of AE CB may warrant a different treatment approach that 
focuses on the exacerbation and CB components. Phenotyp-
ing COPD patients based on exacerbation frequency and 
dominant clinical manifestations are essential to achieving 
a more directed treatment.
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without CB in several recent studies. In the Evaluation of 
COPD Longitudinally to Identify Predictive Surrogate End-
points and Genetic Epidemiology of COPD (COPDGene) 
studies, Agusti et al and Kim et al reported a significantly 
worse SGRQ score in CB patients (all P,0.001); while in 
the Korea COPD Subgroup Study Team, Choi et al reported 
significantly worse CAT (P,0.001) and SGRQ (P,0.001) 
scores in the CB group.30–32 de Oca et al also reported sig-
nificantly poorer respiratory symptoms, including dyspnea 
(P=0.002) and wheezing (P=0.003) as well as general 
HRQoL (P=0.049) measured by Short Form-12 among CB 
patients of the COPD in five Latin America Cities study.33 
In comparison with NON-CB, the airway inflammation of 
COPD that is mediated by neutrophil, macrophage, and 
CD8+ lymphocyte is more aggressive in CB leading to 
more mucus production and small airway obstruction, 
which explains the worse HRQoL.34 In the COPDGene 
and Epidemiologic Study of COPD in Spain study, Hardin 
et al and Miravitlles et al, reported significantly worse 
SGRQ in patients of ACOS (P=0.009 and P,0.001, 
respectively).35,36 The number of subjects of ACOS in 
both of these studies were much more than ours (n=119 
and n=67) and, therefore, both these studies were able to 
show significantly worse HRQoL in patients of ACOS. In 
ACOS, the dual inflammatory processes of COPD and BA 
mediated by eosinophils, mast cells, and CD4+ lymphocytes 
led to poorer HRQoL.37
The present study findings support the importance of 
phenotyping COPD based on exacerbation frequency and 
dominant clinical manifestations according to GesEPOC 
guideline to allow a more personalized treatment. Patients 
with AE CB may warrant a different treatment approach 
that focuses on the exacerbation and CB components 
because they have the poorest HRQoL. Treatment with 
azithromycin to reduce exacerbation frequency and roflu-
milast to control CB symptoms should be added early in 
patients with this phenotype, especially when long-acting 
beta 2-agonist and long-acting muscarinic antagonist fail 
to control the COPD symptoms.20 In order to preserve the 
HRQoL in ACOS, inhaled corticosteroid that controls the 
BA component should be initiated upon diagnosis. Besides, 
other non-pharmacological therapy, such as smoking ces-
sation, pulmonary rehabilitation, and nutritional support 
should be offered early to improve respiratory symptoms 
and HRQoL.
To our knowledge, this is the first study in the Asia–
Pacific region that compares the HRQoL of all the 
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